Suven Life Sciences Ltd
Suven Life Sciences Ltd (SUVEN) last traded at ₹360, a market capitalisation of ₹10,181 crore. Over the past 52 weeks the stock has ranged between ₹124 and ₹394. Suven Life Sciences Ltd last reported results for the quarter ended Jun 2026, with sales of ₹4 crore and net profit of ₹-128 crore. Figures are as of 25 Aug 2026 and are not real time.
Suven Life Sciences Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Suven Life Sciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹4 cr, up 100.0% from ₹2 cr a year earlier. Net profit was ₹-128 cr, down 146.2% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 |
| Expenses | 55 | 41 | 45 | 53 | 81 | 106 | 52 | 136 |
| Operating profit | -52 | -39 | -44 | -51 | -80 | -103 | -51 | -132 |
| OPM % | -2,032% | -2,435% | -2,981% | -2,714% | -8,671% | -3,678% | -3,331% | -3,711% |
| Other income | 4 | 2 | 1 | 1 | 4 | 3 | 7 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net profit | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 |
| EPS (₹) | -2.28 | -1.79 | -2.01 | -2.36 | -3.40 | -4.48 | -1.73 | -4.83 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Suven Life Sciences Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 13 | 12 | 14 | 12 | 7 | 7 | 9 |
| Operating profit | -80 | -122 | -126 | -128 | -166 | -284 | -366 |
| OPM % | -593% | -1,032% | -929% | -1,094% | -2,487% | -3,999% | -4,152% |
| Net profit | -72 | -122 | -118 | -105 | -161 | -276 | -352 |
| EPS (₹) | -3.78 | -5.59 | -5.42 | -4.82 | -7.37 | -10.48 | -14.44 |
TTM is the trailing twelve months to the most recent quarter.
Suven Life Sciences Ltd growth and returns
- 10 Years
- -35%
- 5 Years
- -12%
- 3 Years
- -19%
- TTM
- 17%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -91%
- 10 Years
- 40%
- 5 Years
- 37%
- 3 Years
- 79%
- 1 Year
- 61%
- 10 Years
- -24%
- 5 Years
- -68%
- 3 Years
- -66%
- Last Year
- -82%
Suven Life Sciences Ltd shareholding pattern
Promoters held 65.47% at Jul 2026, down from 67.36% at Sep 2025. FIIs 0.48% and DIIs 2.73%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.26% | 70.26% | 70.26% | 67.36% | 67.36% | 70.15% | 70.08% | 65.47% |
| FIIs | 0.34% | 0.25% | 0.58% | 1.17% | 1.07% | 0.91% | 0.56% | 0.48% |
| DIIs | 1.05% | 0.01% | 0.03% | 3.39% | 3.39% | 4.62% | 2.93% | 2.73% |
| Public | 28.35% | 29.47% | 29.12% | 28.07% | 28.18% | 24.32% | 26.42% | 31.32% |
| No. of shareholders | 63,537 | 64,603 | 66,159 | 64,921 | 64,381 | 63,915 | 66,791 | 66,647 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Suven Life Sciences Ltd corporate filings
- Outcome of 37th Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Suven Life Sciences Limited has successfully concluded its 37th Annual General Meeting…
Read the full analysis - Monitoring Agency Report for the quarter ended 30th June, 2026Company Updatelow impact
Cruxal's analysis: The company has submitted its Monitoring Agency Report for the quarter ended June 30…
Read the full analysis - Newspaper publication- un-audited finacial resultsCompany Updatemedium impact
Cruxal's analysis: Suven Life Sciences Limited has released its unaudited financial results for the quarter…
Read the full analysis - Un-audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026Board Meetingmedium impact
Cruxal's analysis: Suven Life Sciences Limited reported a consolidated net loss of 127.61 crore for the…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Suven Life Sciences Ltd
Cruxal reads every Suven Life Sciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.